FATE Q2 2021 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+145.4% YoY

Gross Profit

-$35M-258.1% margin

Operating Income

-$47M-348.8% margin

Net Income

-$55M-411.1% margin

EPS (Diluted)

$-0.58

QoQ Revenue Growth

+20.4%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$46M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$264M

Stockholders' Equity

$752M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$5M	+145.4%
Gross Profit	-$35M	-$21M	-63.2%
Operating Income	-$47M	-$29M	-63.0%
Net Income	-$55M	-$28M	-96.4%

Revenue Segments

Upfront Fee And Equity Premium

$4M100%